Sermorelin in Adolescents (Ages 12 to 17): How and When to Transition to Adult Care

What Is Sermorelin and Why Is It Used in the 12 to 17 Age Group?

Sermorelin is the acetate salt of a synthetic peptide corresponding to the first 29 amino acids of endogenous GHRH. It stimulates the pituitary somatotrophs to release growth hormone (GH) in a pulsatile, physiologic pattern. In adolescents aged 12 to 17, it appears in clinical practice primarily as a diagnostic tool and, in some off-label protocols, as a growth-support agent when recombinant GH is not tolerated or when a more physiologic stimulation approach is preferred by the prescribing endocrinologist.

Mechanism in a Developing Pituitary

The adolescent pituitary is highly responsive to GHRH input. Puberty itself amplifies GH pulse amplitude through rising estrogen and testosterone, which sensitize somatotrophs. Sermorelin works by binding the GHRH receptor (GHRHR), triggering a cAMP-dependent increase in GH secretion. Unlike exogenous recombinant GH (rhGH), sermorelin preserves the feedback arc: rising IGF-1 suppresses further GH release, which reduces the risk of supraphysiologic IGF-1 accumulation [1].

Why Adolescence Creates a Unique Clinical Window

Between roughly ages 12 and 17, several biological events collide: the pubertal GH surge, rapid linear growth, epiphyseal maturation, and the approach of final adult height. This window is both an opportunity and a deadline. Once growth plates close, the rationale for sermorelin as a growth-promoting agent disappears, and the clinical question shifts entirely to whether the patient has adult GH deficiency (GHD) requiring lifelong management [2].

A 2019 GH Research Society Consensus Statement noted that "the transition period from pediatric to adult care is a high-risk interval for loss of follow-up and inappropriate cessation of GH-related evaluation," underscoring that structured handoff protocols are not optional [3].

How Sermorelin Differs From Recombinant GH in Adolescent Patients

Recombinant human GH (somatropin) directly replaces GH and is the first-line FDA-approved therapy for pediatric GHD. Sermorelin, by contrast, stimulates endogenous GH secretion. This distinction shapes the entire transition strategy.

Pituitary Reserve Testing Implications

Because sermorelin works only when pituitary somatotrophs are functional, a measurable GH response to sermorelin confirms residual pituitary capacity. Patients who respond well to sermorelin during adolescence may have partial rather than complete GHD. This matters at transition: the GH Research Society recommends re-testing all adolescents with childhood-onset GHD using a formal stimulation test (insulin tolerance test or glucagon stimulation) after epiphyseal closure, regardless of prior treatment modality [3].

In a cohort analysis published in the Journal of Clinical Endocrinology and Metabolism (JCEM), approximately 25 to 30% of adolescents diagnosed with isolated idiopathic GHD in childhood did not meet adult GHD criteria on retesting, suggesting the childhood diagnosis may have reflected constitutional delay rather than true pituitary pathology [4].

Dosing Differences Between Age Groups

Adolescent sermorelin protocols typically use 0.2 to 0.3 mg subcutaneously at bedtime, timed to coincide with the natural GH pulse. Adult protocols, if sermorelin is continued post-transition, often begin at 0.2 mg nightly and titrate based on IGF-1 response, with many practitioners targeting an IGF-1 in the mid-normal range for chronological age (roughly 100 to 250 ng/mL in a healthy 20-year-old) [5]. Dose reductions are common at transition because the strong pubertal GH amplification disappears, and the same dose that maintained adequate IGF-1 in a 16-year-old may produce supraphysiologic levels in the same patient at 19.

When to Begin the Transition Process

The transition should not begin the day the patient turns 18. Formal reassessment should start 6 to 12 months before the anticipated end of linear growth, which correlates with bone age rather than chronological age.

Bone Age as the Primary Timing Signal

A left-hand and wrist X-ray interpreted by the Greulich-Pyle method remains the standard for estimating skeletal maturity. When bone age reaches approximately 15.5 to 16 years in females and 16.5 to 17 years in males, epiphyseal fusion is imminent. At that point, the prescribing team should schedule:

1. Repeat IGF-1 and IGFBP-3 off therapy (after a 4-to-6-week washout of sermorelin)
2. A formal GH stimulation test if off-therapy IGF-1 falls below the age-adjusted lower limit of normal
3. MRI of the hypothalamic-pituitary region if not performed within the preceding 24 months, particularly in patients with structural or genetic etiologies [3]

Diagnosis Classification Guides Next Steps

The etiology of the original GHD diagnosis is the strongest predictor of adult GHD persistence. Patients with structural hypothalamic-pituitary abnormalities (e.g., craniopharyngioma, septo-optic dysplasia), radiation history, or multiple pituitary hormone deficiencies have a 75 to 100% probability of confirmed adult GHD on retesting. Those with isolated idiopathic GHD have a 25 to 50% probability [4]. Sermorelin-treated adolescents with idiopathic diagnoses should not be assumed to need lifelong therapy without formal retesting.

The Retesting Protocol: What Labs and Stimulation Tests to Order

Retesting is the clinical linchpin of transition care. Ordering the wrong test, or skipping retesting entirely, exposes patients either to unnecessary lifelong therapy or to untreated adult GHD, which carries metabolic and cardiovascular consequences [6].

Lab Panel at Transition

The minimum lab panel at the start of transition evaluation includes:

• IGF-1 (age- and sex-adjusted Z-score, not just absolute value)
• IGFBP-3 (complements IGF-1, particularly useful when IGF-1 is borderline)
• Fasting glucose and HbA1c (sermorelin and GH both affect insulin sensitivity)
• Fasting lipid panel (adult GHD is associated with an atherogenic lipid profile)
• Thyroid panel (TSH, free T4) to rule out secondary hypothyroidism confounding GH testing
• Morning cortisol if central adrenal insufficiency has not been excluded [7]

A serum IGF-1 Z-score below minus 2.0 after washout, in the correct clinical context, is sufficient to confirm adult GHD without a stimulation test, per the Endocrine Society's 2011 Clinical Practice Guideline on adult GHD [7].

Stimulation Testing Options

When IGF-1 is equivocal (Z-score between minus 1.0 and minus 2.0), a provocative test is required. The insulin tolerance test (ITT) remains the gold standard, with a GH peak <3 ng/mL at adequate hypoglycemia (glucose <40 mg/dL) confirming adult GHD. The glucagon stimulation test (GST) is an acceptable alternative when the ITT is contraindicated, with a cut-point of GH peak <3 ng/mL for patients with BMI <30 kg/m² [7].

The HealthRX Transition Decision Framework for sermorelin-treated adolescents uses three branches based on etiology and retesting results:

Branch A (Structural or multi-hormone deficiency): Proceed directly to adult GHD evaluation; high probability of confirmed diagnosis. Begin adult-dose rhGH or continue sermorelin at adjusted adult dose pending formal confirmation.

Branch B (Isolated idiopathic GHD, IGF-1 Z-score < minus 2.0 off therapy): Confirm with stimulation test; if peak GH <3 ng/mL, transition to adult protocol.

Branch C (Isolated idiopathic GHD, IGF-1 Z-score above minus 1.0 off therapy): High likelihood of constitutional delay, not true GHD. Discontinue sermorelin; monitor annually with IGF-1 for 2 years.

Monitoring Parameters During the Transition Year

The year straddling the end of adolescent care and the start of adult care is when adverse outcomes cluster. A 2016 study in the European Journal of Endocrinology found that 41% of patients with confirmed childhood-onset GHD had a gap of more than 12 months between stopping pediatric-dose GH therapy and initiating adult-dose therapy, during which metabolic markers worsened significantly [8].

IGF-1 Targets

During the transition year, the IGF-1 target shifts. In active puberty, the goal is to maintain IGF-1 in the mid-to-upper normal range for pubertal stage (often 250 to 400 ng/mL during peak puberty). After epiphyseal closure, the adult target is approximately the 50th percentile for chronological age, typically 100 to 250 ng/mL for ages 18 to 25 [5]. Overcorrection above the 97th percentile raises concern for acromegalic effects and should prompt dose reduction.

Glucose and Metabolic Monitoring

Sermorelin raises GH, which has counter-regulatory effects on insulin. Fasting glucose and HbA1c should be checked at baseline and every 6 months during the transition year. Patients who develop fasting glucose above 100 mg/dL may warrant dose reduction or a brief therapy pause, followed by re-evaluation of the risk-benefit balance [9].

Bone Density

Adult GHD is a recognized risk factor for reduced bone mineral density. A dual-energy X-ray absorptiometry (DEXA) scan should be obtained at the end of the adolescent phase to establish a baseline. The International Society for Clinical Densitometry recommends reporting adolescent DEXA results as Z-scores (compared with age-matched peers), not T-scores [10].

Transitioning the Care Team, Not Just the Therapy

Clinical handoff is as important as biochemical reassessment. Pediatric endocrinologists and adult endocrinologists often use different diagnostic thresholds, different preferred stimulation tests, and different comfort levels with sermorelin versus rhGH. A structured handoff should include:

Transfer Documentation Checklist

• Original GHD diagnosis, etiology, and imaging reports
• All GH stimulation test results from childhood
• Growth chart data including peak growth velocity and final height SDS
• Sermorelin dose history and most recent IGF-1 values on therapy
• Summary of any adverse effects during adolescent treatment
• Family history of pituitary pathology (hereditary GHD is relevant to adult prognosis)

Shared Decision-Making With the Adolescent Patient

Patients aged 16 to 17 are cognitively capable of participating meaningfully in treatment decisions. Evidence from transition medicine more broadly shows that involving adolescents in their own care planning improves adherence during the vulnerable post-transition period [11]. The care team should explain, in plain language, why retesting is required even if the patient feels well on current therapy.

Adult Continuation of Sermorelin vs. Switching to Recombinant GH

Once adult GHD is confirmed, the prescribing team faces a choice: continue sermorelin (off-label in adults for growth promotion purposes, though used in some telehealth and longevity medicine contexts) or switch to FDA-approved adult rhGH (somatropin).

Regulatory Field

Sermorelin (Geref, no longer commercially available as the branded product; available as compounded sermorelin acetate through 503B outsourcing facilities) does not carry an FDA indication for adult GHD. Recombinant GH products, including somatropin formulations such as Norditropin, Genotropin, and Humatrope, carry FDA approval for adult GHD and are supported by strong long-term safety data [12].

For patients who have responded well to sermorelin during adolescence, wish to avoid daily rhGH injections, and have confirmed residual pituitary reserve, some adult endocrinologists may elect to continue compounded sermorelin. The evidence base for this choice is limited. Patients should be counseled that compounded sermorelin is not FDA-approved for adult GHD and that rhGH has decades of post-marketing safety surveillance behind it [12].

IGF-1 Monitoring Is the Common Thread

Whether the adult protocol uses sermorelin or rhGH, the monitoring target is the same: IGF-1 Z-score in the zero-to-plus-one range (mid-normal for age). The GH Research Society and Endocrine Society both recommend IGF-1 measurement every 6 months for the first 2 years of adult therapy, then annually once stable [7, 3].

Special Populations Within the 12 to 17 Cohort

Patients With Prior Cranial Radiation

Adolescents who received cranial radiation for central nervous system tumors or leukemia are at high risk for radiation-induced GHD, which can be progressive. GH axis damage is dose-dependent: doses above 30 Gy to the hypothalamic-pituitary axis produce GHD in 50 to 100% of patients within 10 years [13]. For these patients, sermorelin's utility as a stimulation agent is limited if the hypothalamus itself is damaged, since the GHRH receptor on the pituitary may receive inadequate upstream signaling regardless of exogenous GHRH. Retesting at transition is mandatory, and rhGH is typically the adult treatment of choice.

Patients With Turner Syndrome

Turner syndrome patients are not GH-deficient in the classic sense but receive rhGH for height augmentation under a separate FDA indication. Sermorelin is not indicated for Turner syndrome. At transition, these patients move to adult gynecology and endocrinology protocols focused on estrogen replacement and cardiovascular surveillance rather than GH continuation [14].

Patients With Prader-Willi Syndrome

Prader-Willi syndrome (PWS) patients may receive rhGH during childhood for metabolic and body composition benefits. Sermorelin is not standard in PWS. At transition, GH therapy may continue under adult PWS protocols, but the prescribing framework changes, and adult endocrinologists should be aware of the distinct metabolic phenotype [15].

Practical Clinical Timeline: A Month-by-Month Transition Map

The following timeline applies to a typical 17-year-old on sermorelin therapy approaching the end of linear growth:

6 to 12 months before anticipated epiphyseal closure: Order bone age X-ray. Review original diagnosis etiology. Schedule adult endocrinology consultation.

4 to 6 months before closure: Obtain baseline transition labs (IGF-1, IGFBP-3, fasting glucose, HbA1c, lipids, thyroid function, morning cortisol). Begin shared decision-making conversation with patient and family.

At epiphyseal closure (confirmed by bone age X-ray): Discontinue or pause sermorelin for 4 to 6 weeks (washout). Schedule provocative GH stimulation test if indicated by etiology and IGF-1 Z-score.

4 to 8 weeks post-washout: Perform stimulation test if required. Interpret results using adult GHD cut-points (GH peak <3 ng/mL on ITT or GST).

Decision point: Confirm or exclude adult GHD. If confirmed, initiate adult protocol (rhGH preferred per FDA approval; compounded sermorelin only after explicit informed consent regarding off-label status). If excluded, discontinue therapy and monitor IGF-1 annually for 2 years.

Year 1 of adult care: IGF-1 every 6 months. Repeat DEXA at 12 months. Fasting glucose and HbA1c every 6 months. Lipid panel annually [7].